



Financial results for the the year ended March 31, 2024

May 9, 2024

1. Financial results for the year ended March 31, 2024

2. Forecast for the year ending March 31, 2025

The year ended March 31, 2024: Summary

Revenue
¥717.2B

- **YoY: Up ¥89.1B (Up ¥12.2B vs. previous forecast)**
 - Revenue grew in all segments but the Components Business.
 - In the Imaging Products Business, revenue grew on increased sales volumes of mirrorless cameras and interchangeable lenses.
 - In the Precision Equipment Business, revenue grew on increased sales volumes of ArF immersion lithography systems.
 - In the Digital Manufacturing Business, revenue grew on contribution from expanded sales at SLM.

Operating profit
¥39.7B

- **YoY: Down ¥15.2B (Up ¥3.7B vs. previous forecast)**
 - In the Imaging Products Business, profit grew on maintained strength.
 - Total operating profit declined due to decreased profit in the Components Business and the Precision Equipment Business (lower sales volumes of FPD lithography systems and lower service revenue), and one-time costs in the Healthcare Business and the Digital Manufacturing Business.

**Profit attributable
to owners of parent**
¥32.5B

- **YoY: Down ¥12.4B (Up ¥5.5B vs. previous forecast)**

Dividends
¥50

- **YoY: Up ¥5 (Same as previous forecast)**
 - Interim ¥25 and year-end ¥25

Note: Amounts in this statement are rounded down to the hundred millions of yen.

The year ended March 31, 2024: Financial Highlights

Billions of Yen	FY2023/3	Previous Forecast	FY2024/3	Change		Change	
	Actual (A)	(Feb. 8) (B)	Actual (C)	Amount (C)-(A)	% (C)/(A)	Amount (C)-(B)	% (C)/(B)
Revenue	628.1	705.0	717.2	+89.1	+14.2%	+12.2	+1.7%
Operating profit % vs Revenue	54.9 8.7%	36.0 5.1%	39.7 5.5%	-15.2 -3.2P	-27.6%	+3.7 +0.4P	+10.5%
Profit before tax % vs Revenue	57.0 9.1%	37.0 5.2%	42.6 5.9%	-14.4 -3.2P	-25.2%	+5.6 +0.7P	+15.3%
Profit attributable to owners of parent % vs Revenue	44.9 7.2%	27.0 3.8%	32.5 4.5%	-12.4 -2.7P	-27.5%	+5.5 +0.7P	+20.6%
FCF	-112.1	-	-10.6	+101.5	-	-	-
ROE	7.4%	4.2%	5.0%	-2.4P	-	+0.8P	-
EPS	¥125.46	¥77.96	¥94.03	-¥31.43	-	+¥16.07	-
Annual Dividends	¥45	¥50	¥50	+¥5	-	±¥0	-
Exchange Rate: US\$	¥135	¥143	¥145	Impact on Revenue			
				+30.6		+6.8	
EURO	¥141	¥154	¥157	Impact on Operating profit			
				+5.9		+1.3	

FCF was negative as construction costs for our new HQ building outweighed a substantial improvement in operating CF and the sale of ¥16.6B in cross-shareholdings.


Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.3M shares

The year ended March 31, 2024: Performance by Segment

Billions of Yen		FY2023/3	Previous Forecast	FY2024/3	Change		Change	
		Actual (A)	(Feb. 8) (B)	Actual (C)	Amount (C)-(A)	% (C)/(A)	Amount (C)-(B)	% (C)/(B)
Imaging Products Business	Revenue	227.1	275.0	279.7	+52.6	+23.2%	+4.7	+1.7%
	Operating profit	42.2	44.0	46.5	+4.3	+10.3%	+2.5	+5.8%
	% vs Revenue	18.6%	16.0%	16.6%	-2.0P		+0.6P	
Precision Equipment Business	Revenue	203.2	213.0	219.3	+16.1	+7.9%	+6.3	+3.0%
	Operating profit	24.5	12.0	15.1	-9.4	-38.2%	+3.1	+26.5%
	% vs Revenue	12.1%	5.6%	6.9%	-5.2P		+1.3P	
Healthcare Business	Revenue	99.3	105.0	107.8	+8.5	+8.5%	+2.8	+2.8%
	Operating profit	11.5	6.5	5.3	-6.2	-53.5%	-1.2	-17.1%
	% vs Revenue	11.7%	6.2%	5.0%	-6.7P		-1.2P	
Components Business	Revenue	53.0	47.0	47.0	-6.0	-11.4%	±0.0	+0.0%
	Operating profit	22.0	15.0	16.8	-5.2	-23.8%	+1.8	+12.2%
	% vs Revenue	41.6%	31.9%	35.8%	-5.8P		+3.9P	
Digital Manufacturing Business	Revenue	42.0	62.0	59.9	+17.9	+42.4%	-2.1	-3.3%
	Operating profit	-10.1	-13.0	-15.8	-5.7	-	-2.8	-
	% vs Revenue	-24.1%	-21.0%	-26.4%	-2.3P		-5.4P	
Others (incl. Corporate expenses, etc.)	Revenue	3.2	3.0	3.2	±0.0	+2.2%	+0.2	+9.9%
	Operating profit	-35.3	-28.5	-28.3	+7.0	-	+0.2	-
Consolidated	Revenue	628.1	705.0	717.2	+89.1	+14.2%	+12.2	+1.7%
	Operating profit	54.9	36.0	39.7	-15.2	-27.6%	+3.7	+10.5%
	% vs Revenue	8.7%	5.1%	5.5%	-3.2P		+0.4P	

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Imaging Products Business



Digital Camera-Interchangeable Lens type (units: 1,000)

Market Scale	5,810	6,100	6,200
Nikon	700	800	800

Interchangeable Lens (units:1,000)

Market Scale	9,400	9,800	9,870
Nikon	1,160	1,250	1,250


• Revenue: Up ¥52.6B YoY (Up ¥4.7B vs. previous forecast)

- DCIL market expanding mainly in China.
- Nikon's new products (Z 8 and Z f) are selling well.
- Nikon advanced its shift to mirrorless cameras and interchangeable lenses.
- Revenue substantially grew YoY as sales volumes of mirrorless cameras and interchangeable lenses grew and ASP rose. The weaker yen also helped.
- Revenue beat the previous forecast due to changes in product mix and the weaker yen.

• Operating Profit: Up ¥4.3B YoY (Up ¥2.5B vs. previous forecast)

- Operating profit grew YoY as the effects of revenue growth outweighed increased parts procurement prices and sales promotion costs.
- Operating profit beat the previous forecast because of increased revenue.

The year ended March 31, 2024: Precision Equipment Business



- **Revenue: Up ¥16.1B YoY (Up ¥6.3B vs. previous forecast)**

- Revenue grew YoY in the overall Precision Equipment Business as higher sales volumes in mainly ArF immersion lithography systems outweighed a substantial decline in FPD lithography system sales volumes due to customers reining in capital expenditure.
- Compared to previous forecast, sales volumes of refurbished lithography systems and service revenue increased.

- **Operating Profit: Down ¥9.4B YoY (Up ¥3.1B vs. previous forecast)**

- Operating profit for the overall Precision Equipment Business declined YoY on lower sales volumes of FPD lithography systems and lower service revenue in the Semiconductor Lithography Business.
- Operating profit beat the previous forecast because of increased revenue.

FPD Lithography Systems (units)


Market Scale (CY22/23)	79	46	46
Nikon	29	16	16

Semiconductor Lithography Systems (New/Refurbished, units)

Market Scale (CY22/23)	480	520	520
Nikon	27/18	30/12	31/15

Note: FY2023/3 results have been re-stated to reflect segmentation changes.

The year ended March 31, 2024: Healthcare Business



* See Contingent Liabilities (page 30) of our Consolidated Financial Results.


• Revenue: Up ¥8.5B YoY (Up ¥2.8B vs. previous forecast)

- Revenue grew on increased sales in Life Science and Contract Cell Manufacturing as well as the weaker yen.
- In Life Science, we made progress developing the private sector market and delivering solutions for drug discovery support. However, sales decelerated in 2H on increased market uncertainty.
- In Eye Care, sales was flat YoY as expanded sales in China and the rest of Asia was offset by the disappearance of major deals struck.
- In Contract Cell Manufacturing, multiple projects progressed smoothly, and sales expanded.

• Operating Profit: Down ¥6.2B YoY (Down ¥1.2B vs. previous forecast)

- Operating profit declined YoY as rising procurement costs, higher R&D expenditures and investments in people and IT systems, and the accrual of ¥4.1B in one-time costs outweighed profit boosting effects of increased revenue.
- The one-time costs were primarily in Eye Care. A ¥1.4B provision* booked in Q2, related survey expenses, and the disposal and write-down of inventories.
- Results missed previous forecast due to increased one-time costs in Eye Care and smaller sales volumes of microscopes.

The year ended March 31, 2024: Components Business



Note: FY2023/3 results have been re-stated to reflect segmentation changes.


- **Revenue: Down ¥6.0B YoY (Same level as previous forecast)**

- Sales declined YoY in EUV related components and optical parts due to postponed capital expenditures and reduced utilization rates by semiconductor device makers.
- Encoder sales declined YoY due to stagnant demand in the factory automation market.
- Sales of photomask substrates for FPD declined YoY due to market stagnation.

- **Operating Profit: Down ¥5.2B YoY
(Up ¥1.8B vs. previous forecast)**

- Operating profit beat the previous forecast due to product mix improvement.

The year ended March 31, 2024: Digital Manufacturing Business



- Revenue: Up ¥17.9B YoY (Down ¥2.1B vs. previous forecast)**
 - Revenue grew due to the full-year contribution from SLM.
 - On a standalone basis, SLM revenue grew 15%* YoY, a record high.
 - Results missed previous forecast due to the impact on the Industrial Equipment Business from market stagnation in semiconductors and electronic components.
- Operating Profit: Down ¥5.7B YoY (Down ¥2.8B vs. previous forecast)**
 - Operating losses expanded YoY. In the Advanced Manufacturing (ADM) Business, ¥4.0B in intangible-asset amortization costs resulting from the SLM acquisition and increased costs launching a base of operations in the US outweighed reductions in acquisition and restructuring costs.
 - On a standalone basis, SLM turned profitable for the first time in Q4.
 - Compared to previous forecast, the ADM Business progressed as planned. In the Industrial Metrology Business, we forecasted being profitable, but results were negative. That was due to missing plan for revenue and the accrual of ¥1.7B in one-time costs including impairment of development assets and disposal and write-down of inventories due to rationalization of unprofitable products.

Note: FY2023/3 results have been re-stated to reflect segmentation changes.
* SLM standalone revenue growth (%) is expressed based on local currency (EURO).

1. Financial results for the year ended March 31, 2024

2. Forecast for the year ending March 31, 2025

Forecast for the year ending March 31, 2025: Summary

Revenue
¥745.0B

- **YoY: Up ¥27.8B**
 - The Imaging Products Business revenue to grow on increased sales volumes and the consolidation of RED Digital Cinema (RED).
 - The Healthcare Business and the Digital Manufacturing Business to further expand businesses.
 - The Precision Equipment Business and the Components Business revenue to decline because of postponed investments at some semiconductor customers.

Operating profit
¥35.0B

- **YoY: Down ¥4.7B**
 - We expect operating profit to decline as profit growth and a reduction in one-time costs in the Healthcare Business and the Digital Manufacturing Business are outweighed by profit contraction in the Imaging Products Business and an increase in corporate expenses (¥5.0B HQ relocation costs and IT-related investments).

**Profit attributable
to owners of parent**
¥30.0B

- **YoY: Down ¥2.5B**

Dividends
¥55

- **Annual dividend planned: ¥55, up ¥5 YoY** (interim ¥25 and year-end ¥30)
 - Step up dividends to reach our target of annualized ¥60 in the last fiscal year of the Medium-Term Management Plan.

Exchange rate

- **US\$ ¥145, EURO ¥155**

Forecast for the year ending March 31, 2025: Financial Highlights

Billions of Yen	FY2024/3	FY2025/3	Change	
	Actual (A)	Forecast (B)	Amount (B)-(A)	% (B)/(A)
Revenue	717.2	745.0	+27.8	+3.9%
Operating profit	39.7	35.0	-4.7	-12.0%
% vs Revenue	5.5%	4.7%	-0.8P	
Profit before tax	42.6	40.0	-2.6	-6.3%
% vs Revenue	5.9%	5.4%	-0.5P	
Profit attributable to owners of parent	32.5	30.0	-2.5	-7.9%
% vs Revenue	4.5%	4.0%	-0.5P	
ROE	5.0%	4.3%	-0.7P	-
EPS	¥94.03	¥86.59	-¥7.44	-
Annual Dividends	¥50	¥55	+¥5	-
Exchange Rate: US\$	¥145	¥145	Impact on Revenue	
			-0.6	
EURO	¥157	¥155	Impact on Operating profit	
			-0.3	

Note: The numbers of issued shares assumed for EPS forecast calculation: approx. 346.5M shares

Shareholder Returns Policy in the period of the Medium-Term Management Plan

	FY2022/3	FY2023/3	FY2024/3	FY2025/3	FY2026/3
		Medium-Term Management Plan (4 years)			
Dividends	¥40 Year-End ¥20 Interim ¥20	¥45 (Up ¥5) Year-end ¥25 Interim ¥20	¥50 (Up ¥5) Year-end ¥25 Interim ¥25	¥55 planned (Up ¥5) Year-end ¥30 Interim ¥25	¥60 target Annual ¥60
Share buyback	-	¥30.0B (Approx. 5.7% of outstanding shares)	-	Opportunistic share buyback of ¥30.0B+ during period of our Medium-Term Management Plan	
Cancellation of treasury stock	-	26M shares (7.6% of outstanding shares before cancellation)	-	Repurchased our shares are to be cancelled in principle	
Total shareholder returns	34.4%	102.0%	53.2%	Targeted 40% or higher	
Sale of cross-shareholdings (Resource of buyback)	¥19.9B	¥1.2B	¥16.6B	Sell more moving forward	

Total shareholder returns has been trending at or above the targeted 40%.
Step up dividends to reach annualized ¥60 in FY2026/3.

Revision of business segment (From FY2025/3)

<u>Old Segment</u>	<u>Business Unit (BU)</u>		<u>Business Unit (BU)</u>	<u>New Segment</u>
Imaging Products	Imaging Products BU		Imaging Products BU	Imaging Products
Precision Equipment	Precision Equipment Group	FPD Lithography BU	FPD Lithography BU	Precision Equipment
		Semiconductor Lithography BU	Semiconductor Lithography BU	
Healthcare	Healthcare BU		Healthcare BU	Healthcare
Components	Customized Products BU		Customized Products BU	Components
	Glass BU		Glass BU	
	Digital Solutions BU		Industrial Solutions BU	
Digital Manufacturing	Industrial Metrology BU		Advanced Manufacturing (ADM) BU	Digital Manufacturing
	Advanced Manufacturing (ADM) BU			
Others	Others		Others	Others
Corporate expenses, etc.	Headquarters division of the parent company		Headquarters division of the parent company	Corporate expenses, etc.




Former Industrial Metrology BU to be disclosed as a part of the Components Business.
 The Digital Manufacturing Business is comprised solely the Advanced Manufacturing (ADM) BU.

Forecast for the year ending March 31, 2025: Forecast by Segment (New Segment)

Billions of Yen		FY2024/3	FY2025/3	Change	
		Actual (A)	Forecast (B)	Amount (B)-(A)	% (B)/(A)
Imaging Products Business	Revenue	279.7	300.0	+20.3	+7.2%
	Operating profit	46.5	44.0	-2.5	-5.5%
	% vs Revenue	16.6%	14.7%	-1.9P	
Precision Equipment Business	Revenue	219.3	215.0	-4.3	-2.0%
	Operating profit	15.1	15.0	-0.1	-1.2%
	% vs Revenue	6.9%	7.0%	+0.1P	
Healthcare Business	Revenue	107.8	115.0	+7.2	+6.6%
	Operating profit	5.3	11.0	+5.7	+104.1%
	% vs Revenue	5.0%	9.6%	+4.6P	
Components Business	Revenue	85.9	85.0	-0.9	-1.1%
	Operating profit	15.1	17.0	+1.9	+12.4%
	% vs Revenue	17.6%	20.0%	+2.4P	
Digital Manufacturing Business	Revenue	21.0	28.0	+7.0	+33.3%
	Operating profit	-14.0	-9.5	+4.5	-
	% vs Revenue	-67.1%	-33.9%	+33.2P	
Others (incl. Corporate expenses, etc.)	Revenue	3.2	2.0	-1.2	-39.4%
	Operating profit	-28.3	-42.5	-14.2	-
Consolidated	Revenue	717.2	745.0	+27.8	+3.9%
	Operating profit	39.7	35.0	-4.7	--12.0%
	% vs Revenue	5.5%	4.7%	-0.8P	

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

Forecast for the year ending March 31, 2025: Imaging Products Business



- **Revenue: Up ¥20.3B YoY**

- The overall DCIL market remains stable. The mid/high-end model market is expected to expand.
- We continue to focus on mid/high-end models and expect sales volume and revenue to grow.
- We acquired US cinema camera manufacturer RED in April 2024. We aim to expand the fast-growing professional digital cinema market.

- **Operating Profit: Down ¥2.5B YoY**

- Operating profit to decline on cost increases including RED acquisition-related expenses and R&D.


Digital Camera-Interchangeable Lens type (units: 1,000)

Market Scale	6,200	6,100
Nikon	800	850

Interchangeable Lens (units:1,000)

Market Scale	9,870	9,600
Nikon	1,250	1,350

Forecast for the year ending March 31, 2025: Precision Equipment Business



- **Revenue: Down ¥4.3B YoY**

- We expect to flat revenue YoY overcoming a reduction in ArF lithography systems sales volumes with a substantial increase in sales volumes of G8 FPD lithography systems for high-resolution panels.

- **Operating Profit: Down ¥0.1B YoY**

- Semiconductor lithography system profit to contract on decreased sales volumes of ArF lithography systems. However, the overall Precision Equipment Business operating profit is projected to remain flat YoY on profit growth from an increase in revenue in FPD lithography systems and an improvement in service revenue in the Semiconductor Lithography Business.

FPD Lithography Systems (units)


Market Scale (CY23/24)	46	60
Nikon	16	39

Semiconductor Lithography Systems (New/Refurbished, units)

Market Scale (CY23/24)	520	600
Nikon	31/15	24/11

Note: From FY25/3, CY24 market scale of semiconductor lithography system includes lithography system for 200mm or smaller.

Forecast for the year ending March 31, 2025: Healthcare Business



• Revenue: Up ¥7.2B YoY

- In Life Science, we expect to grow sales by developing the private sector market and strengthening drug discovery support service, despite concerns about customers reining in investments in the face of elevated interest rates in Western economies and impacts from the US federal budget.
- In Eye Care, projecting sales growth in core North America as well as Asia and all other geographical markets.
- In Contract Cell Manufacturing, projecting revenue growth driven by expansion of existing projects.


• Operating Profit: Up ¥5.7B YoY

- Operating profit to grow on increased revenue and decreased one-time costs, including the Eye Care provision*.

Breakdown of one-time costs	FY24/3 Results	FY25/3 Forecast
Provision and related one-time costs in Eye Care (Addition in the provision in the above amount)	¥3.8B (¥1.4B)	¥1.0B (N/A)
Other	¥0.3B	N/A
Total one-time costs	¥4.1B	¥1.0B

* See Contingent Liabilities (page 30) of our Consolidated Financial Results.

Forecast for the year ending March 31, 2025: Components Business



• Revenue: Down ¥0.9B YoY

- Projecting a decline in sales of optical components and EUV related components due to a later-than-expected recovery in demand related to semiconductors.
- Sales of photomask substrate for FPD to increase on market recovery.
- Measuring instruments such as video measuring systems and X-ray and CT systems to be flat YoY.

• Operating Profit: Up ¥1.9B YoY


- Projecting operating profit growth due to the disappearance of ¥2.0B in one-time costs including the fixed asset impairment losses booked in the Industrial Solutions Business* in the previous year.

Breakdown of one-time costs	FY24/3 Results	FY25/3 Forecast
Former Digital Solutions Business	¥0.3B	N/A
Former Industrial Metrology Business	¥1.7B	N/A
Total Industrial Solutions Business	¥2.0B	N/A

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

* The former Industrial Metrology BU, which had been included in the Digital Manufacturing Business, is disclosed as a part of the Components Business. Effective April 2024, the former Industrial Metrology BU has been integrated with the former Digital Solutions BU and became the Industrial Solutions BU.

Forecast for the year ending March 31, 2025: Digital Manufacturing Business



• Revenue: Up ¥7.0B YoY

- The metal 3D printer market is expected to see growth mainly on large-format systems by demand increase in aerospace and defense industries.
- We project revenue growth on strong orders for SLM's large-format metal 3D printer (NXG series).
- In FY2024/3, SLM's annual orders booked grew 40% YoY, a record high. As of the end of March 2024, the order backlog had grown to ¥10.0B level.

• Operating Profit: Up ¥4.5B YoY

- The size of the operating loss is projected to contract on the effects of revenue growth and the disappearance of one-time costs (¥1.8B).
- SLM aims to turn profitable based on full-year EBITDA.

Note: FY2024/3 results have been re-stated to reflect segmentation changes.

Former Industrial Metrology BU to be disclosed as a part of the Components Business. Digital Manufacturing Business is solely of the ADM BU.

FY2025/3 estimation of intangible-asset amortization costs resulting from the SLM acquisition: ¥3.6B